The ticagrelor market size has grown strongly in recent years. It will grow from $1.93 billion in 2025 to $2.08 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to limited availability of antiplatelet therapies, growing cardiovascular disease prevalence, expansion of hospital pharmacy networks, increasing clinical trials for cardiovascular drugs, rising awareness of heart attack and stroke risks.
The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to launch of extended-release ticagrelor tablets, expansion of retail and online pharmacy distribution, rising adoption of personalized cardiovascular treatment, increasing government initiatives for cardiovascular disease prevention, integration with digital health monitoring systems. Major trends in the forecast period include rising use of ticagrelor in acute coronary syndrome management, growing preference for oral antiplatelet therapy over injectable options, expansion of hospital and ambulatory cardiology services, increasing awareness of stroke and myocardial infarction prevention, development of extended-release ticagrelor formulations.
The increasing prevalence of cardiovascular diseases is expected to propel the growth of the ticagrelor market going forward. Cardiovascular diseases are a group of conditions that affect the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. The rising prevalence of cardiovascular diseases is mainly driven by poor dietary habits, as high intake of saturated fats, trans fats, added sugars, and sodium contributes to obesity, high blood pressure, and elevated cholesterol levels, which are key risk factors for heart-related conditions. Ticagrelor helps manage cardiovascular diseases by inhibiting platelet aggregation and reducing the formation of blood clots. It improves clinical outcomes by lowering the risk of heart attacks and strokes, particularly among high-risk patients. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4% increase from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ticagrelor market.
Major companies operating in the ticagrelor market are concentrating on securing regulatory approvals to broaden product indications, improve market access, and strengthen their competitive position. Regulatory approvals are official authorizations granted by government agencies that allow a product to be marketed and sold after confirming its safety, quality, and effectiveness. For example, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic ticagrelor tablets in the 90 mg strength and tentative approval for the 60 mg strength. These tablets are indicated to reduce the risk of cardiovascular events by preventing platelet aggregation and clot formation.
In May 2023, SERB Pharmaceuticals, a Luxembourg-based pharmaceutical company, partnered with SFJ Pharmaceuticals Inc. to advance the development of a ticagrelor reversal agent. This collaboration aims to support clinical development, secure U.S. regulatory approval, and commercialize bentracimab, a reversal agent designed to rapidly neutralize ticagrelor’s antiplatelet effects in patients requiring emergency surgery or experiencing major bleeding. SFJ Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in ticagrelor reversal agents.
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.
North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ticagrelor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the ticagrelor market by increasing import costs for raw materials and active pharmaceutical ingredients (APIs), impacting tablet manufacturing and formulation processes. Segments such as extended-release tablets and hospital pharmacy distribution are particularly affected, with regions like Asia-Pacific and Europe experiencing higher production expenses. While tariffs raise costs and create supply chain adjustments, they also encourage local API manufacturing, domestic production, and innovation in formulation efficiencies, strengthening long-term market resilience.
The ticagrelor market research report is one of a series of new reports that provides ticagrelor market statistics, including ticagrelor industry global market size, regional shares, competitors with a ticagrelor market share, detailed ticagrelor market segments, market trends and opportunities, and any further data you may need to thrive in the ticagrelor industry. This ticagrelor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ticagrelor is an oral antiplatelet drug primarily prescribed to lower the risk of stroke, heart attack, and other cardiovascular events in patients with acute coronary syndrome (ACS) or a prior myocardial infarction. It functions by inhibiting platelet aggregation, thereby preventing the formation of blood clots in the arteries. This mechanism helps improve blood circulation and reduces the risk of subsequent cardiovascular complications.
The main types of ticagrelor include 90 mg tablets and 60 mg tablets. The 90 mg ticagrelor tablet is a prescription medication used to prevent thrombotic events in patients with acute coronary syndrome or a history of heart attack. It belongs to drug classes such as antiplatelet and antithrombotic agents and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Key applications include the management of acute coronary syndrome, myocardial infarction, stroke prevention, and other cardiovascular conditions, and it is used by end users such as hospitals and clinics, ambulatory centers, and other healthcare settings.
The ticagrelor market consists of sales of branded oral tablets, generic ticagrelor formulations, fixed-dose combination products, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The ticagrelor market size is expected to see strong growth in the next few years. It will grow to $2.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to launch of extended-release ticagrelor tablets, expansion of retail and online pharmacy distribution, rising adoption of personalized cardiovascular treatment, increasing government initiatives for cardiovascular disease prevention, integration with digital health monitoring systems. Major trends in the forecast period include rising use of ticagrelor in acute coronary syndrome management, growing preference for oral antiplatelet therapy over injectable options, expansion of hospital and ambulatory cardiology services, increasing awareness of stroke and myocardial infarction prevention, development of extended-release ticagrelor formulations.
The increasing prevalence of cardiovascular diseases is expected to propel the growth of the ticagrelor market going forward. Cardiovascular diseases are a group of conditions that affect the heart and blood vessels, including coronary heart disease, heart failure, stroke, and hypertension. The rising prevalence of cardiovascular diseases is mainly driven by poor dietary habits, as high intake of saturated fats, trans fats, added sugars, and sodium contributes to obesity, high blood pressure, and elevated cholesterol levels, which are key risk factors for heart-related conditions. Ticagrelor helps manage cardiovascular diseases by inhibiting platelet aggregation and reducing the formation of blood clots. It improves clinical outcomes by lowering the risk of heart attacks and strokes, particularly among high-risk patients. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, representing a 4% increase from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiovascular diseases is driving the growth of the ticagrelor market.
Major companies operating in the ticagrelor market are concentrating on securing regulatory approvals to broaden product indications, improve market access, and strengthen their competitive position. Regulatory approvals are official authorizations granted by government agencies that allow a product to be marketed and sold after confirming its safety, quality, and effectiveness. For example, in May 2025, Alembic Pharmaceuticals Ltd., an India-based pharmaceutical company, received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for generic ticagrelor tablets in the 90 mg strength and tentative approval for the 60 mg strength. These tablets are indicated to reduce the risk of cardiovascular events by preventing platelet aggregation and clot formation.
In May 2023, SERB Pharmaceuticals, a Luxembourg-based pharmaceutical company, partnered with SFJ Pharmaceuticals Inc. to advance the development of a ticagrelor reversal agent. This collaboration aims to support clinical development, secure U.S. regulatory approval, and commercialize bentracimab, a reversal agent designed to rapidly neutralize ticagrelor’s antiplatelet effects in patients requiring emergency surgery or experiencing major bleeding. SFJ Pharmaceuticals Inc. is a US-based pharmaceutical company specializing in ticagrelor reversal agents.
Major companies operating in the ticagrelor market are AstraZeneca PLC, Merck KGaA, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Limited, Cadila Pharmaceuticals Limited, Alkem Laboratories, Alembic Pharmaceuticals Limited, CCL Pharmaceuticals, Neuland Laboratories, Jiangxi Synergy Pharmaceutical Co. Ltd., Leeford Healthcare Limited, Scimplify, JAMP Pharma Corporation, Actoverco Pharmaceutical Company, CTX Lifesciences Private Limited, DM Pharma, Hema Pharmaceuticals Pvt. Ltd., Chia-Tai Tianqing Pharmaceutical Group Co. Ltd., Biophar Lifesciences Pvt. Ltd., PhaseBio Pharmaceuticals Inc.
North America was the largest region in the ticagrelor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ticagrelor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ticagrelor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have affected the ticagrelor market by increasing import costs for raw materials and active pharmaceutical ingredients (APIs), impacting tablet manufacturing and formulation processes. Segments such as extended-release tablets and hospital pharmacy distribution are particularly affected, with regions like Asia-Pacific and Europe experiencing higher production expenses. While tariffs raise costs and create supply chain adjustments, they also encourage local API manufacturing, domestic production, and innovation in formulation efficiencies, strengthening long-term market resilience.
The ticagrelor market research report is one of a series of new reports that provides ticagrelor market statistics, including ticagrelor industry global market size, regional shares, competitors with a ticagrelor market share, detailed ticagrelor market segments, market trends and opportunities, and any further data you may need to thrive in the ticagrelor industry. This ticagrelor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ticagrelor is an oral antiplatelet drug primarily prescribed to lower the risk of stroke, heart attack, and other cardiovascular events in patients with acute coronary syndrome (ACS) or a prior myocardial infarction. It functions by inhibiting platelet aggregation, thereby preventing the formation of blood clots in the arteries. This mechanism helps improve blood circulation and reduces the risk of subsequent cardiovascular complications.
The main types of ticagrelor include 90 mg tablets and 60 mg tablets. The 90 mg ticagrelor tablet is a prescription medication used to prevent thrombotic events in patients with acute coronary syndrome or a history of heart attack. It belongs to drug classes such as antiplatelet and antithrombotic agents and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies. Key applications include the management of acute coronary syndrome, myocardial infarction, stroke prevention, and other cardiovascular conditions, and it is used by end users such as hospitals and clinics, ambulatory centers, and other healthcare settings.
The ticagrelor market consists of sales of branded oral tablets, generic ticagrelor formulations, fixed-dose combination products, and combination therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Ticagrelor Market Characteristics
3. Ticagrelor Market Supply Chain Analysis
4. Global Ticagrelor Market Trends and Strategies
5. Ticagrelor Market Analysis of End Use Industries
7. Global Ticagrelor Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Ticagrelor Total Addressable Market (TAM) Analysis for the Market
9. Ticagrelor Market Segmentation
90 mg Tablet, 60 mg Tablet
10. Ticagrelor Market Regional and Country Analysis
11. Asia-Pacific Ticagrelor Market
12. China Ticagrelor Market
13. India Ticagrelor Market
14. Japan Ticagrelor Market
15. Australia Ticagrelor Market
16. Indonesia Ticagrelor Market
17. South Korea Ticagrelor Market
18. Taiwan Ticagrelor Market
19. South East Asia Ticagrelor Market
20. Western Europe Ticagrelor Market
21. UK Ticagrelor Market
22. Germany Ticagrelor Market
23. France Ticagrelor Market
24. Italy Ticagrelor Market
25. Spain Ticagrelor Market
26. Eastern Europe Ticagrelor Market
27. Russia Ticagrelor Market
28. North America Ticagrelor Market
29. USA Ticagrelor Market
30. Canada Ticagrelor Market
31. South America Ticagrelor Market
32. Brazil Ticagrelor Market
33. Middle East Ticagrelor Market
34. Africa Ticagrelor Market
36. Ticagrelor Market Competitive Landscape and Company Profiles
37. Ticagrelor Market Other Major and Innovative Companies
40. Ticagrelor Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Ticagrelor Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses ticagrelor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ticagrelor? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ticagrelor market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: 90 mg Tablet; 60 mg Tablet2) By Drug Class: Antiplatelet Agents; Antithrombotic Agents
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By Application: Acute Coronary Syndrome; Myocardial Infarction; Stroke Prevention; Other Applications
5) By End User: Hospitals And Clinics; Ambulatory Centers; Other End Users
Companies Mentioned: AstraZeneca PLC; Merck KGaA; Boehringer Ingelheim International GmbH; Sun Pharmaceutical Industries Limited; Dr. Reddy’s Laboratories Limited; Cadila Pharmaceuticals Limited; Alkem Laboratories; Alembic Pharmaceuticals Limited; CCL Pharmaceuticals; Neuland Laboratories; Jiangxi Synergy Pharmaceutical Co. Ltd.; Leeford Healthcare Limited; Scimplify; JAMP Pharma Corporation; Actoverco Pharmaceutical Company; CTX Lifesciences Private Limited; DM Pharma; Hema Pharmaceuticals Pvt. Ltd.; Chia-Tai Tianqing Pharmaceutical Group Co. Ltd.; Biophar Lifesciences Pvt. Ltd.; PhaseBio Pharmaceuticals Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Ticagrelor market report include:- AstraZeneca PLC
- Merck KGaA
- Boehringer Ingelheim International GmbH
- Sun Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Limited
- Cadila Pharmaceuticals Limited
- Alkem Laboratories
- Alembic Pharmaceuticals Limited
- CCL Pharmaceuticals
- Neuland Laboratories
- Jiangxi Synergy Pharmaceutical Co. Ltd.
- Leeford Healthcare Limited
- Scimplify
- JAMP Pharma Corporation
- Actoverco Pharmaceutical Company
- CTX Lifesciences Private Limited
- DM Pharma
- Hema Pharmaceuticals Pvt. Ltd.
- Chia-Tai Tianqing Pharmaceutical Group Co. Ltd.
- Biophar Lifesciences Pvt. Ltd.
- PhaseBio Pharmaceuticals Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.08 Billion |
| Forecasted Market Value ( USD | $ 2.75 Billion |
| Compound Annual Growth Rate | 7.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
